Welcome!

News Feed Item

Cynapsus Therapeutics Awarded Second Grant from The Michael J. Fox Foundation for Parkinson's Research

TORONTO, ONTARIO -- (Marketwired) -- 07/08/14 -- Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(OTCQX:CYNAF) today announced that it has been awarded a new grant of US$500,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support clinical studies to develop APL-130277, a sublingual thin film strip reformulation of apomorphine. This second MJFF grant will be used to fund the Company's CTH-105 clinical study.

APL-130277 is an easy-to-administer, fast-acting and proprietary reformulation of apomorphine for sublingual delivery. Injectable apomorphine is the only approved drug in the United States, Europe, Japan and other countries for the acute rescue of "off" motor symptoms of Parkinson's disease. The APL-130277 thin film strip system technology is specifically designed to provide enhanced convenience and eliminate buccal mucosal irritation, among other attributes.

CTH-105 is a pilot study in patients with Parkinson's disease who are naive to the use of apomorphine and who experience at least one daily "off" episode with a total duration of "off" in any 24-hour period of at least 2 hours. This study is planned to examine the effect of APL-130277 on relieving "off" episodes over a single day with a dose-titration used to determine dose strengths necessary for future clinical development. This study and future trials of APL-130277 will be listed on Fox Trial Finder, an online tool from MJFF matching interested research volunteers with recruiting clinical studies.

"The options for patients living with 'off' episodes are limited and unfavorable," says Maurizio Facheris, MD, MSc, Associate Director of Research Programs at MJFF. "Initial results of Cynapsus' novel formulation (APL-130277) show this therapy may offer not only a more palatable solution for motor fluctuations, but also a longer window of efficacy, thereby postponing dopamine replacement dosing and lessening associated side effects."

"This second grant from The Michael J. Fox Foundation is very important to Cynapsus, as it solidifies the partnership we have forged with the Foundation to focus on improving the daily lives of Parkinson's patients," said Mr. Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus. "The CTH-105 clinical trial is our first in Parkinson's patient study of APL-130277 and will assist us with dosing information required for the CTH-300a registration study, which is expected to begin in Q4 2014."

Dr. Albert Agro, the Principal Investigator for the study and the Chief Medical Officer of Cynapsus added: "The continued support of The Michael J. Fox Foundation validates our clinical approach and justifies the need for an improved formulation of apomorphine in the form of APL-130277. With the help of the MJFF, we are excited about moving APL-130277 in to patients this summer in the CTH-105 Phase 2 study."

The MJFF previously awarded Cynapsus an initial grant of USD$947,925 to complete a comparative study of APL-130277 (i.e. CTH-103) versus subcutaneous injection. The results of the CTH-103 study were announced on January 13, 2014.

Support for Future Parkinson's Research

Parkinson's disease is a chronic, degenerative neurological disorder that results from the loss of dopamine-producing nerve cells in the brain. Current treatments for Parkinson's disease are able to reduce the symptoms of the disease but are not able to treat the underlying neurodegenerative processes. It is estimated that over one million people in the United States and 4 to 6 million people globally are living with Parkinson's disease. According to the U.S. National Institute of Neurodegenerative Disease and Stroke, the average age of onset is 60, though some people are diagnosed at age 40 or younger.

As part of the MJFF grant agreement, Cynapsus has made a commitment to support further Parkinson's research by making up to $1 million in contributions to MJFF based on future potential sales of APL-130277.

About Apomorphine

Apomorphine, a potent dopamine agonist, is the only drug approved specifically for the treatment of acute motor fluctuations/hypomobility (freezing or "off" episodes) in patients with advanced Parkinson's disease. Presently, apomorphine is administered by intermittent subcutaneous injection usually via a pre-filled injection pen, or, in some cases outside the United States, by continuous infusion pump. Drawbacks associated with subcutaneous injection therapy for patients and caregivers include aversion to needles, the need for multiple injections, which can be painful and are often associated with irritation and inflammation at the injection site, and the requirement for a degree of manual dexterity that some Parkinson's patients find difficult.

About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from "off" episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application ("NDA") expected to be submitted in 2016.

Over one million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. Based on a recent study and the results of the Corporation's Global 500 Neurologists Survey, it is estimated that between 25 percent and 50 percent of Parkinson's patients experience "off" episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses.

More information about Cynapsus (TSX VENTURE:CTH)(OTCQX:CYNAF) is available at www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus' business disclosed under the heading "Risk Factors" in its March 26, 2014, Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor the OTCQX International has approved or disapproved the contents of this press release.

Contacts:
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
[email protected]

Cynapsus Therapeutics
Albert Agro
Chief Medical Officer
(416) 703-2449 x252
[email protected]
www.cynapsus.ca

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Cryptomage, Inc. is a dynamic hi-tech ICT company offering products and services in the cybersecurity area. We deliver high quality solutions both technologically and conceptually. We have academic roots and hire scientists, cybersecurity experts, software developers and analysts. Our strategy is focused on maintaining the highest skills of our human resources. The Cryptomage team is capable of more than delivering complex solutions; we can improve the whole concept to deliver real added value t...
In addition to 22 Keynotes and General Sessions, attend all FinTechEXPO Blockchain "education sessions" plus 40 in two tracks: (1) Enterprise Cloud (2) Digital Transformation. PRICE EXPIRES AUGUST 31, 2018. Ticket prices: ($295-Aug 31) ($395-Oct 31) ($495-Nov 12) ($995-Walk-in) Does NOT include lunch.
Early Bird Registration Discount Expires on August 31, 2018 Conference Registration Link ▸ HERE. Pick from all 200 sessions in all 10 tracks, plus 22 Keynotes & General Sessions! Lunch is served two days. EXPIRES AUGUST 31, 2018. Ticket prices: ($1,295-Aug 31) ($1,495-Oct 31) ($1,995-Nov 12) ($2,500-Walk-in)
It cannot be overseen or regulated by any one administrator, like a government or bank. Currently, there is no government regulation on them which also means there is no government safeguards over them. Although many are looking at Bitcoin to put money into, it would be wise to proceed with caution. Regular central banks are watching it and deciding whether or not to make them illegal (Criminalize them) and therefore make them worthless and eliminate them as competition. ICOs (Initial Coin Offer...
DevOpsSUMMIT at CloudEXPO will expand the DevOps community, enable a wide sharing of knowledge, and educate delegates and technology providers alike. Recent research has shown that DevOps dramatically reduces development time, the amount of enterprise IT professionals put out fires, and support time generally. Time spent on infrastructure development is significantly increased, and DevOps practitioners report more software releases and higher quality. Sponsors of DevOpsSUMMIT at CloudEXPO will b...
Today we introduced our New York & Silicon Valley combo sponsorship and exhibit opportunities with unmatched pre and post-show promotion. At CloudEXPO | DevOpsSUMMIT | DXWorldEXPO NY & CA, Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune...
FinTech Is Now Part of the CloudEXPO New York Program. Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expensive intermediate processes from their businesses. Accordingly, attendees at the upcoming 22nd CloudEXPO | DXWorldEXPO November 12-13, 2018 in New York City will find fresh new content in two new tracks called: FinTechEXPO New York Blockchain E...
In addition to 22 Keynotes and General Sessions, pick from 40 technical sessions in two tracks: (1) DevOpsSUMMIT (2) Cloud-Native & Serverless. EXPIRES AUGUST 31, 2018. Ticket prices: ($295-Aug 31) ($395-Oct 31) ($495-Nov 12) ($595-Walk-in) Does NOT include lunch. DevOps Institue Certification DevOps Institute Two-Day DevOps Certification Program EXPIRES AUGUST 31, 2018. Ticket prices: ($995-Aug 31) ($1,095-Oct 31) ($1,195-Nov 12) ($1,395-Walk-in)
Enterprises are universally struggling to understand where the new tools and methodologies of DevOps fit into their organizations, and are universally making the same mistakes. These mistakes are not unavoidable, and in fact, avoiding them gifts an organization with sustained competitive advantage, just like it did for Japanese Manufacturing Post WWII.
Only Adobe gives everyone - from emerging artists to global brands - everything they need to design and deliver exceptional digital experiences. Adobe Systems Incorporated develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. The Company's Digital Media segment provides tools and solutions that enable individuals, small and medium businesses and enterprises to cre...
Despite being the market leader, we recognized the need to transform and reinvent our business at Dynatrace, before someone else disrupted the market. Over the course of three years, we changed everything - our technology, our culture and our brand image. In this session we'll discuss how we navigated through our own innovator's dilemma, and share takeaways from our experience that you can apply to your own organization.
Blockchain has numerous revolutionary ambitions, but technology hasn’t evolved enough to make them practical. What is the best use of blockchain technology today? How are asset owners and managers looking at blockchain to transform ownership structures? How will blockchain technology allow global investors to access new markets? What kinds of companies will take advantage of blockchain technology as a more efficient way to raise capital?
This session describes how Professional Services organisations can deliver within Technology-as-a-Service (IaaS) constructs, in private and public enterprise cloud scenarios. See how professional services can be packaged and funded by IaaS cash flows, based upon consumption of technology services. Learn how significant, IT infrastructure transformations can be funded through OPEX spending models with multi-year As-a-Services based contracts. Understand how the automation of repeatable services c...
Since their inception, Total Uptime has been delivering on their promise of unprecedented uptime to major brands as well as Fortune 500 corporations in the United States and around the world. Their Cloud network spans 17 countries and delivers the unique ability to seamlessly route Internet traffic from one site to the next when our customers need us to. It is built on the best SSAE 16 SOC 2 Type 2 and CSAE 3416 Datacenters and boasts an impressive line-up of Network and Transit Provider Redunda...
​Blockchain, also known as Distributed Ledger Technology (DLT), can be used for more than just crypto currencies. This presentation discusses how blockchain and the Internet of Things (IOT) can be used for several supply chain management and logistics use cases. Real world examples that utilize the open source project Hyperledger will be discussed.